Allogene Therapeutics (ALLO) currently reports a gross profit of $36M as of June 2026. That compares with $-22K in the prior-year period — up 163890.9% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Allogene Therapeutics's gross profit history and peer comparisons.

Allogene Therapeutics's gross profit increased from $-22K to $36M — a 163890.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Allogene Therapeutics's gross profit of $36M is lower than the Healthcare sector average of $67B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Allogene Therapeutics reported $36M in gross profit as of June 2026. That compares with $-22K in the prior-year period — up 163890.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $36M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Allogene Therapeutics, and consider following ALLO for alerts when major investors trade the stock.